Home » Cystic Fibrosis Drug Development Is Subject of EMEA Guideline
Cystic Fibrosis Drug Development Is Subject of EMEA Guideline
December 17, 2009
Drugmakers have received the first European Medicines Agency (EMEA) guideline on developing products to treat cystic fibrosis. Includes the full text of CHMP Guideline on Clinical Development of Cystic Fibrosis Drugs.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor